Morgan Stanley Downgrades QLT Inc (QLTI) to Underweight
More News related to QLTI
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Morning Movers 11/27: HEB, FAZ, QLTI Higher; ING, LYG, GNV, GAF Lower
- QLT Inc. (QLTI) Shares Higher as RBC Upgrades to Outperform
- Unusual 11 Mid-Day Movers 11/25: RTK, QADI, QBC, KBX Higher; BNHNA, DRAM, TBH, CWTR Lower
- QLT (QLTI) Settles Litigation with General Hospital of Massachusetts
More News related to Downgrades
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Morgan Stanley downgrades QLT Inc (Nasdaq: QLTI) from Equalweight to Underweight.
QLT Inc. is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, photodynamic therapy and Atrigel.
Related Categories
DowngradesStocks Mentioned
+0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
